Source: Eur Respir J 2002; 19: 928-935
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Willaert W., Daenen M., Bomans P., Verleden G., Decramer M.. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?. Eur Respir J 2002; 19: 928-935

Member's Comments

No comment yet.

Related content which might interest you: The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003 Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001 Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Source: Eur Respir J 2003; 21: 260-266 Year: 2003 A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002 Modern treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 60S-66S Year: 2001 Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006 Mechanism by which inhaled bronchodilators prevent exacerbations in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 The role of bronchodilator treatment in the prevention of exacerbations of COPD Source: Eur Respir J 2012; 40: 1545-1554 Year: 2012 The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001 Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history Source: Eur Respir J 2011; 38: 553-560 Year: 2011 Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD Source: Annual Congress 2006 - COPD therapy Year: 2006 Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001 Inhaled corticosteroids and hospitalisation due to exacerbation of COPD Source: Eur Respir J 2003; 22: 286-289 Year: 2003 Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 903-908 Year: 2001 Medical personnel‘s ability to use pressurized metered dose inhaler (pMDI) in India Source: Annual Congress 2006 - The challenges of managing asthma in primary care Year: 2006 Audit of inhaled corticosteroid prescription in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - COPD: management Year: 2010 Where current pharmacological therapies fall short in COPD: symptom control is not enough Source: Eur Respir Rev 2007; 16: 98-104 Year: 2007 A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations Source: Eur Respir J 2013; 41: 12-17 Year: 2013 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004